Canopy Growth Corp Stock
-
Your prediction
Canopy Growth Corp Stock
Pros and Cons of Canopy Growth Corp in the next few years
Pros
Cons
Performance of Canopy Growth Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Canopy Growth Corp | - | - | - | - | - | - | - |
| Bausch Health Companies Inc. | 0.250% | -1.118% | 35.431% | -6.811% | -0.151% | -70.452% | -63.449% |
| Catalent Inc. | -0.370% | 0.391% | 1.392% | 24.671% | 30.874% | -53.915% | 24.397% |
| Opko Health Inc. | 2.180% | 2.056% | -8.535% | -7.419% | -5.253% | -56.644% | -29.424% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Canopy Growth Corporation (US symbol: CGC), a key player in the pharmaceutical industry, reveals a complex picture characterized by significant challenges and a few potential strengths. The company has faced considerable hurdles in terms of profitability, as evidenced by its recent income statements, balance sheets, and cash flow reports. Despite these adversities, there are factors that could shape its trajectory positively in the future.
Advantages:
Diversified Revenue Streams: Canopy Growth's revenue from its operations stood at approximately CAD 297 million, which, while not indicative of profitability, suggests that the company possesses a diverse set of revenue sources. This might provide some level of resilience in an uncertain market.
